Category: Trick or Trade

An Evaluation of Biotech Firms

An Evaluation of Biotech Firms

A Comprehensive Essay Part 2 In Part 1 of our comprehensive essay series Vertex (VRTX) was the first firm we used to make a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms. In Part 2, Vertex remains our case in point. In Part 1 we acknowledged that we picked VRTX on March 18, 2011 at $44.39. The question is: Why …
An Evaluation of Biotech Firms

An Evaluation of Biotech Firms

A Comprehensive Essay Part 1 Yes, we have stories to tell about some of our picked stocks which proved to be highly successful after being condemned by erroneous evaluations from unfair analysts. Some of these firms faced problems that are not unusual for drug designing and developing firms. While trying to overcome their obstacles, the firms in question were faced with unfortunate debilitating attacks by …